Brian Gallagher


  • LocationBoston
  • ExpertiseVenture Capital


Mary-Ellen Craig

Tel: + 781 466 8800

Brian has more than 20 years of investing, business development, operational and R&D experience in both biotechnology and large pharmaceutical companies. He joined Abingworth in October 2018 and sources and supports deals across a wide range of therapeutic areas and stages of development from start-ups to late-stage venture capital investments. He was formerly a board member at Nimbus Therapeutics, Aileron Therapeutics and Navitor Pharmaceuticals and is currently on the board of Translate Bio.

Previously, Brian was a Partner at SR One, the venture capital arm of GlaxoSmithKline (GSK), where he established the company’s Boston office. He was formerly Senior Director of Corporate Development at Sirtris Pharmaceuticals where he played a key role in post-merger integration after the company’s acquisition by GSK. Earlier in his career, Brian held key roles in R&D at Alantos Pharmaceuticals and at Eisai. Brian holds a PhD in Organic Chemistry from the University of Michigan, is an inventor on over 25 patents and patent applications and is the senior author of a number of publications in prominent journals. He currently serves on the Investment Advisory Board for University of Michigan Monroe-Brown Biomedical Seed Fund, the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society.